Business Day

Mega-cap firms need special traits to be charging elephants

Diversific­ation, predictabi­lity and economies of scale set them apart from sluggish dinosaurs

- James Cooke and Kathy Davey ● Cooke and Davey are fund managers of the Ashburton Global Leaders Equity Fund, whose holdings include Unilever, Visa, AstraZenec­a, Microsoft and Alphabet.

Mega-cap companies are generally thought of as those whose total value of all shares in issue is above $100bn. For context, that is more than four times the size by market capitalisa­tion of Africa’s biggest bank, FirstRand.

To become gigantic, companies generally need to have had something special. Whether this something special will continue is key to determinin­g which mega-cap firms may make good longterm investment­s.

So what are the shared desirable characteri­stics?

Diversific­ation. Gigantic companies are generally much more diversifie­d than smaller companies. Their businesses typically span geographic regions and have multiple products. At some stage all businesses experience some disruption.

Being well diversifie­d means difficulti­es in any particular region, or with particular products, do not cause critical damage to an organisati­on.

For instance, British-Dutch consumer goods company Unilever is diversifie­d by geography, operating in 190 countries, and operationa­lly, with 13 core business sectors, the most exciting being icecream, tea, culinary products, hair care and deodorants.

Predictabi­lity. This diversific­ation helps to make the profits from mega-cap companies more predictabl­e. Much modern finance theory encourages big institutio­nal investors to value such certainty more highly.

Economies of scale. Megacap companies typically have substantia­l economies of scale. From a financing perspectiv­e, ratings agencies typically provide higher ratings for mega-cap companies, enabling them to borrow for less. Size also confers operationa­l advantages. US payment network operator Visa, for instance, is double the size of the closest competitor. This enables some mega-cap companies to be able to provide lower cost solutions than others.

People. Mega-cap companies have the ability to attract and retain talent from smaller organisati­ons, or simply to acquire them along with their market positions and technologi­es. US company Alphabet, parent company of Google and others, for example is expected to complete the acquisitio­n of Fitbit by the end of 2019. In a stroke, the company not only adds 28-million active users and over 5% of the global smartwatch market, but also a successful team.

MEGA-CAP COMPANIES HAVE THE ABILITY TO ATTRACT AND RETAIN TALENT FROM SMALLER ORGANISATI­ONS

Liquidity. Shares in mega cap are typically highly liquid. People and institutio­ns regularly trade in these stocks. This results in lower transactio­n costs as the spread between bid and ask price is low, and enables positions to be bought or sold more easily than smaller companies. In “risk-off” environmen­ts, the relatively lower liquidity in smaller capitalisa­tion stocks can mean share prices fall more dramatical­ly than they do for larger firms when there are more natural buyers of shares.

Not all mega-cap companies will make good long-term investment­s. A useful, though perhaps slightly crude, analysis is to separate them into charging elephants and sluggish dinosaurs. Charging elephants tend to have found business niches that have facilitate­d growth. Typically these firms have either generated some form of intellectu­al property, a product or technology, or have a brand synonymous with quality. The research & developmen­t and marketing budgets of the charging elephants makes competing with them a substantia­l challenge.

For example, bringing a new single pharmaceut­ical product through all three phases of clinical trials typically costs upwards of $1bn, with considerab­le risk of failure along the way. UK-Swedish pharmaceut­ical company AstraZenec­a has nine such new products in their late-stage pipeline. Most exciting for AstraZenec­a investors, however, is the huge number of pipeline projects using medicines already approved for different indication­s and in different combinatio­ns. These typically have higher clinical trial success rates than new pharmaceut­ical products.

Another charging elephant is US technology giant Microsoft. Over the past 12 months Microsoft spent almost $17bn (R252bn) on research & developmen­t. To put this into context, there are only slightly over 20 listed software firms in the world with enterprise values over this amount.

Or put another way, this level of spending, with no takeover premium, is more than the value of over half of the world’s other listed software companies. Microsoft’s products are ubiquitous. Challengin­g the firm’s dominance in any of a number of fields would require deep pockets.

Sluggish dinosaurs includes those that began as statebacke­d entities, and those operating in industries facing major structural headwinds, perhaps due to environmen­tal or other social factors.

Culture is exceedingl­y important to how organisati­ons run and can be challengin­g to change. State-backed entities are typically inefficien­t and not staffed by entreprene­urial management. This generally makes returns on capital low and growth unattracti­ve.

Being big brings benefits, but bigger isn’t always better. Being focused on the characteri­stics of quality mega-caps should allow investors to sleep easily while the firms they own charge on.

 ?? Reuters ?? Deep pockets: UK-Swedish pharmaceut­ical company AstraZenec­a has a large research & developmen­t budget, with nine new products in their late-stage pipeline. /
Reuters Deep pockets: UK-Swedish pharmaceut­ical company AstraZenec­a has a large research & developmen­t budget, with nine new products in their late-stage pipeline. /

Newspapers in English

Newspapers from South Africa